- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04314687
Stem Cell and Conditioned Medium for Cerebral Palsy
June 12, 2022 updated by: PT. Prodia Stem Cell Indonesia
Allogeneic Umbilical Cord Mesenchymal Stem Cells and Conditioned Medium for Cerebral Palsy in Children
The aim of this study was to compare the effectiveness of umbilical cord mesenchymal stem cells (UCMSCs) and conditioned medium (CM) administration, UCMSCs only and control with standard therapy.
Hypothesis: UCMSCs + CM therapy resulting in higher improvement in cognitive function, gross motor function and chemical factors than UCMSCs and standard therapy.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
78
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hardiono D. Pusponegoro
- Phone Number: 088293176579
- Email: hardionodp@gmail.com
Study Contact Backup
- Name: Cynthia Retna Sartika
- Email: c.sartika@gmail.com
Study Locations
-
-
-
Jakarta, Indonesia
- Recruiting
- Indonesian National Brain Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 months to 3 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosed as Cerebral palsy with total body involvement type
- Age between 6 month - 3 years old
- Parents requesting for cell therapy
- The parents give sign in informed consent form do to examination, therapy, blood sampling collection and observation for their child
Exclusion Criteria:
- Head circumference less than -3 SD (more than 3 cm) Nellhaus standard
- Have diagnosed meningitis and encephalitis
- Have diagnosed congenital infection i.e. toxoplasmosis, rubella congenital, cytomegalovirus
- Have diagnosed metabolic disorder, chromosome disorder, congenital malformation or neuroregeneratif disease
- Progressive disorder
- Regressive development disorder
- Severe anatomical abnormalities in Brain MRI
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: UCMSCs + CM
UCMSCs + CM is administered via intrathecal injection
|
The umbilical cord was removed from the donor and brought to cell culture facility immediately.
Upon arrival, pre-sterility sample testing was performed to ensure the sample was free from contaminant.
Culture processes were conducted in a laboratory room where high sterility and safety were guaranteed.
Every batch of the cells was monitored by a series of quality control testing to assure the quality of the product.
Other Names:
Conditioned medium collected from umbilical cord mesenchymal stem cell (UC-MSC) cultured.
Every batch of the conditioned medium was monitored by a series of quality control testing to assure the quality of the product.
Other Names:
|
Experimental: UCMSCs
UCMSCs is administered via intrathecal injection
|
The umbilical cord was removed from the donor and brought to cell culture facility immediately.
Upon arrival, pre-sterility sample testing was performed to ensure the sample was free from contaminant.
Culture processes were conducted in a laboratory room where high sterility and safety were guaranteed.
Every batch of the cells was monitored by a series of quality control testing to assure the quality of the product.
Other Names:
|
Active Comparator: Standard Therapy
Physiotherapy
|
Standard therapy for cerebral palsy such as physiotherapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gross Motor Function
Time Frame: 3 month after stem cells
|
Gross Motor Function Classification System (GMFCS)
|
3 month after stem cells
|
Gross Motor Function
Time Frame: 6 month after stem cells
|
Gross Motor Function Classification System (GMFCS)
|
6 month after stem cells
|
Gross Motor Function
Time Frame: 3 month after stem cells
|
Gross Motor Function Measure (GMFM)
|
3 month after stem cells
|
Gross Motor Function
Time Frame: 6 month after stem cells
|
Gross Motor Function Measure (GMFM)
|
6 month after stem cells
|
Cognitive Function
Time Frame: 3 month after stem cells
|
Bayley Scales of Infant Development (BSID) version III
|
3 month after stem cells
|
Cognitive Function
Time Frame: 6 month after stem cells
|
Bayley Scales of Infant Development (BSID) version III
|
6 month after stem cells
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Chemical Marker
Time Frame: 3 month after stem cells
|
Insulin-like growth factor 1 (IGF-1); stromal derived factor-1α (SDF-1α); brain derived neurotrophic factors (BDNF), Vascular endothelial growth factor (VEGF),glial cell line-derived neutrophic factor (GDNF), fibroblast growth factor (FGF), Doublecortin (DCX)
|
3 month after stem cells
|
Chemical Marker
Time Frame: 6 month after stem cells
|
Insulin-like growth factor 1 (IGF-1); stromal derived factor-1α (SDF-1α); brain derived neurotrophic factors (BDNF), Vascular endothelial growth factor (VEGF),glial cell line-derived neutrophic factor (GDNF), fibroblast growth factor (FGF), Doublecortin (DCX)
|
6 month after stem cells
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 13, 2021
Primary Completion (Anticipated)
September 25, 2023
Study Completion (Anticipated)
December 25, 2023
Study Registration Dates
First Submitted
February 20, 2020
First Submitted That Met QC Criteria
March 17, 2020
First Posted (Actual)
March 19, 2020
Study Record Updates
Last Update Posted (Actual)
June 14, 2022
Last Update Submitted That Met QC Criteria
June 12, 2022
Last Verified
June 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CT/CP/02/2020
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cerebral Palsy
-
Gazi UniversityCompletedCerebral Palsy | Cerebral Palsy, Spastic | Cerebral Palsy Spastic Diplegia | Cerebral Palsy Quadriplegic | Cerebral Palsy, MonoplegicTurkey
-
Northwestern UniversityActive, not recruitingCerebral Palsy | Diplegic Cerebral Palsy | Bilateral Cerebral PalsyUnited States
-
Centre Médico-Chirurgical de Réadaptation des Massues...RecruitingCerebral Palsy, Dyskinetic | Cerebral Palsy, Spastic | Infantile Hemiplegic Cerebral PalsyFrance
-
St Mary's University CollegeUniversity of GloucestershireUnknownCerebral Palsy | Cerebral Palsy Ataxic | Cerebral Palsy, MixedUnited Kingdom
-
Hilde FeysHasselt University; ETH Zurich; Curtin UniversityRecruitingHemiplegic Cerebral Palsy | Cerebral Palsy, SpasticBelgium
-
University of California, San FranciscoNational Institutes of Health (NIH)RecruitingDystonic Cerebral Palsy | Dyskinetic Cerebral PalsyUnited States
-
MTI UniversityEnrolling by invitationSpastic Diplegic Cerebral PalsyEgypt
-
East Carolina UniversityRecruitingHemiplegic Cerebral Palsy | Unilateral Cerebral Palsy | Remote Ischemic ConditioningUnited States
-
October 6 UniversityCompletedSpastic Cerebral Palsy | Spastic Hemiplegic Cerebral PalsyEgypt
-
Marmara UniversityUnknownCerebral Palsy, Spastic | Cerebral Palsy, Spastic, DiplegicTurkey
Clinical Trials on Umbilical Cord Mesenchymal Stem Cells
-
Acibadem UniversityUnknownDuchenne Muscular DystrophyTurkey
-
Limin RongCompleted
-
Qingdao UniversityUnknownDilated CardiomyopathyChina
-
Qingdao UniversityUnknownUlcerative Colitis | Mesenchymal Stem Cells | Umbilical CordChina
-
Qingdao UniversityUnknownDiabetes Mellitus | Diabetes Mellitus, Type 1 | Mesenchymal Stem Cells | Umbilical CordChina
-
Shenzhen Beike Bio-Technology Co., Ltd.The Second Affiliated Hospital of Kunming Medical UniversityUnknown
-
Central South UniversityUnknown
-
Institute of Hematology & Blood Diseases HospitalCompletedPeripheral Arterial Disease
-
Translational BiosciencesCompleted
-
Allergy and Asthma Consultants, Wichita, KansasAidan Foundation; Neil H. Riordan PhDCompletedDuchenne's Muscular DystrophyUnited States